Does Tirzepatide Cause Hair Loss?

Hair loss on tirzepatide affects a minority of people, with reported rates of roughly 4% to 5% in clinical trials. That is around one in twenty, and it is meaningfully higher than the 1% reported on placebo.

According to the FDA prescribing information for Zepbound, hair loss was reported by 5% of participants on 5 mg, 4% on 10 mg and 5% on 15 mg, compared with 1% on placebo.

The figures come from a pooled analysis of two placebo-controlled weight management trials including 2,519 adults.

There is no clear dose relationship in that data. Rates were essentially flat across 5 mg, 10 mg and 15 mg, which is worth noting because a higher dose does not appear to mean more shedding.

Sex makes a much bigger difference than dose. The Zepbound label reports hair loss in 7.1% of female participants versus 0.5% of male participants, compared with 1.3% of women and 0% of men on placebo.

One more figure is worth stating plainly: no Zepbound-treated patient discontinued treatment because of hair loss in those trials. One placebo-treated patient did.

A labelling difference worth understanding. Hair loss is listed as an adverse reaction in the Zepbound prescribing information but is not listed in the Mounjaro® prescribing information, despite both containing tirzepatide.

This reflects what was recorded in different trial populations, not a difference in the molecule. Mounjaro trials studied people with type 2 diabetes, where average weight loss was smaller.

Whether tirzepatide directly causes hair loss, rather than triggering it indirectly, is genuinely unresolved, and the evidence has shifted recently. The honest answer is that the mainstream explanation is being questioned by newer data.

The established explanation is that hair loss on tirzepatide is a downstream effect of rapid weight loss rather than a direct action on hair follicles.

The FDA prescribing information supports this, stating explicitly that hair loss adverse reactions in Zepbound-treated patients were associated with weight reduction. Rapid weight loss from any cause, including bariatric surgery, illness and restrictive dieting, is a well-documented trigger for the same shedding pattern.

The newer evidence is less tidy. A large retrospective cohort study published in the Journal of the American Academy of Dermatology in February 2026 used the TriNetX network to compare people prescribed semaglutide or tirzepatide against matched controls taking metformin.

The US analysis matched 576,250 patients per group, over 1.1 million people in total.

That study found a significantly increased risk of new-onset hair loss across several diagnostic categories, including telogen effluvium, androgenetic alopecia and alopecia areata.

The finding that complicates the standard explanation is this: the authors observed that BMI reductions in their cohort were modest over time, and concluded that hair loss risk may not be fully explained by rapid or extreme weight loss alone.

A separate 2026 cohort analysis published in JAAD International reached a similar conclusion, reporting increased risk of non-scarring hair loss among GLP-1 receptor agonist users, particularly telogen effluvium.

What this means in practice. Rapid weight loss is clearly a major contributor and is the mechanism with the strongest supporting evidence. Whether it is the only mechanism is now an open question.

A 2026 systematic review in Science Progress concluded that evidence points to increased hair loss risk with semaglutide and tirzepatide, with rapid weight loss a likely contributor particularly for telogen effluvium.

Anyone telling you this is definitively settled, in either direction, is ahead of the evidence.

Telogen effluvium is a temporary form of diffuse hair shedding caused by a large number of hair follicles entering their resting phase at the same time, then shedding together a few months later.

It is the most common cause of sudden hair loss and the pattern most often described in people losing weight rapidly.

Your hair does not grow continuously. Each follicle cycles through phases.

• Anagen (growth): roughly 85% to 90% of scalp follicles at any time, lasting several years.
• Catagen (transition): a brief regression phase lasting a few weeks.
• Telogen (rest): roughly 5% to 15% of follicles, lasting about three months before the hair sheds.

Under significant physiological stress, that balance shifts. Research indicates that as many as 70% of hairs in the growth phase can prematurely switch into the resting phase.

Those hairs do not fall out straight away. They sit in the follicle for the duration of the resting phase, then shed more or less together.

Normal shedding is roughly 50 to 100 hairs a day. In telogen effluvium, that can rise several times over, which is why it appears so alarming in the shower or on a pillow.

Shedding from telogen effluvium typically begins 2 to 4 months after the trigger, not at the time of the trigger, which is a slower clock than how quickly tirzepatide works. The delay equals the length of the resting phase, which averages around three months.

This is the single most useful fact for working out what is happening to you. If you started tirzepatide in January and noticed shedding in April, the timing fits.

If you noticed shedding in the first three weeks, something other than telogen effluvium is more likely and is worth investigating.

The delay also creates a cruel irony. Shedding often peaks when your weight loss is going well, months after the change that triggered it. The trigger has usually already passed by the time you see the consequence.

Telogen effluvium presents as diffuse thinning across the whole scalp rather than bald patches. The hairline is usually preserved, the scalp looks healthy, and there is no scarring, redness or pain. Ponytails feel thinner and the part looks wider.

Telogen effluvium and pattern hair loss are different conditions with different outcomes, and telling them apart matters because the response differs. One usually resolves on its own. The other progresses without treatment.

Rapid weight loss can do something specific and under-discussed here. It can trigger telogen effluvium and unmask androgenetic alopecia that was already developing quietly. When enough resting hairs shed at once, thinning that was previously hidden becomes visible.

That is why some people find their hair does not fully return to its previous density even after the shedding stops. The telogen effluvium resolved. The pattern loss underneath it did not.

Clinical literature makes this point directly: recovery from telogen effluvium is generally spontaneous within six months, unless a background of pattern alopecia is present.

Both can occur at the same time. If you are unsure which you have, that is a question for a clinician rather than a self-assessment.

Rapid weight loss triggers hair shedding because hair is a low-priority tissue when the body is in an energy deficit. Follicles are among the fastest-dividing cells in the body and are metabolically expensive to run.

When resources tighten, hair growth is one of the first things deprioritised.

Several mechanisms operate at once. Sustained caloric deficit signals scarcity. Protein intake often falls, and hair is largely made of keratin, a protein. Micronutrient intake can drop alongside total food volume, and iron, zinc and vitamin D status all influence hair growth.

Here is the part specific to tirzepatide, and it matters more than the drug question. Tirzepatide works by suppressing appetite. That is the intended effect. But it also removes the signal that would normally tell you that you have not eaten enough.

Under-eating on tirzepatide is easy and quiet. You are not fighting hunger and losing. You simply are not hungry, so you eat less without registering how much less.

Protein is usually the first casualty, because protein-rich foods are the most filling and the least appealing when appetite is suppressed.

Someone dieting without medication gets hungry, and hunger is feedback. On tirzepatide that feedback is dampened. The result is that inadequate intake can continue for weeks without anything feeling wrong, until something like hair shedding surfaces months later.

That is why this side effect is worth taking as information rather than just as a cosmetic problem. It often signals that intake needs attention.

This is exactly what regular check-ins catch. Appetite suppression working as intended can tip into under-eating without you noticing, and the consequences show up months later. A supervised program tracks protein adequacy and intake patterns while you are still able to change them.

Hair lost through telogen effluvium usually grows back, because the follicles are not damaged. They are resting, not dead, which is what makes this pattern reversible.

The realistic timeline looks roughly like this, with wide individual variation.

• Months 1-3 of shedding: heavy loss, often at its most alarming. The trigger has usually already passed.
• Around month 3-4: shedding rate typically begins to slow as follicles re-enter the growth phase.
• Months 3-6: most acute cases have settled. Fine, short new hairs commonly appear along the hairline and part.
• Months 6-12: density gradually rebuilds. Hair grows roughly half an inch per month, so recovery is slow to see.

Clinical sources indicate the large majority of acute telogen effluvium cases resolve. That said, “usually” is not “always,” and this article will not promise you regrowth.

Early regrowth is easy to miss and easy to misread. Those short wispy hairs at the hairline are frequently mistaken for breakage. They are usually the opposite: new growth.

What makes regrowth slower or less complete:

• Ongoing rapid weight loss. The trigger is still active, so new hairs keep entering the resting phase.
• Continued inadequate protein or nutrient intake. Worth raising with your provider or coach.
• Underlying pattern hair loss that the shedding has unmasked.
• Untreated thyroid disease, iron deficiency or another medical cause. These are worth ruling out.
• Shedding continuing beyond six months, which meets the definition of chronic telogen effluvium and warrants assessment.

You cannot reliably prevent hair shedding on tirzepatide, but you can address the factors most likely to be driving it. All of them relate to the mechanism rather than to hair products.

• Prioritise protein, deliberately. Appetite suppression makes it easy to under-eat protein without noticing. Ask your provider or coach what intake is appropriate for you, since the right amount depends on your body and your dose.
• Avoid pushing loss faster than necessary. The more rapid the loss, the stronger the trigger. Dose and pace are a conversation with your prescriber, not something to adjust yourself.
• Ask about nutrient testing if shedding is significant. Iron and ferritin, vitamin D, zinc and thyroid function are the usual candidates. Testing tells you whether supplementing is warranted, which guessing does not.
• Do not start supplements speculatively. Correcting a deficiency you actually have is useful. Taking supplements without a documented deficiency has weak supporting evidence, and some can interfere with lab results.
• Handle your hair gently. Loose styles, less heat, less tension. This does not treat the cause, but it avoids adding breakage on top of shedding.
• Protect sleep and manage stress where you can. Both influence the hair cycle, and both are frequently disrupted during significant weight loss.
• Talk to your provider before changing anything about your medication. Stopping abruptly because of hair loss is rarely the right first move, and it is not a decision to make alone.

Most tirzepatide-related shedding does not need specialist assessment. Some does, and the criteria are reasonably clear.

Contact your prescriber if:

• Shedding continues beyond about six months without improvement.
• Shedding started within the first few weeks of treatment, which does not fit the telogen effluvium pattern.
• You also have fatigue, cold intolerance, or changes to your periods, which may point to thyroid or iron issues.
• You are struggling to eat enough, or suspect your protein intake is inadequate.

See a dermatologist if:

• Hair loss is patchy or in discrete circles rather than diffuse.
• Your scalp is visible in specific areas rather than generally thinner.
• Your hairline is receding or your part is widening in a defined pattern.
• The scalp itself is red, scaly, itchy or painful.
• Loss is severe enough to be significantly affecting your wellbeing.

A dermatology workup typically involves examining the scalp and hair, a pull test, questions about timing and triggers, and blood tests covering thyroid function, iron studies and vitamin D.

The purpose is to distinguish telogen effluvium from pattern hair loss, alopecia areata and other causes, because the treatments differ.

Earlier assessment is better if pattern hair loss is a possibility, since available treatments work better before substantial loss has occurred.

Hair shedding is often the first visible sign that intake has drifted too low. By the time you see it, it has usually been happening for months.

The useful question is rarely just does tirzepatide cause hair loss. It is whether the pace of your weight loss and your intake are being watched by anyone. That is what structured support is for. Not hair products, but regular review of protein adequacy, the pace of your weight loss, and whether your dose is right for you. Concerns get raised while they are still fixable rather than months later.

If your hair is shedding, talk to your provider before changing anything about your medication.